Time To Seriously Take Stock Of Our Treatment Of Coronavirus?

Even as the world awaits the elusive Corona Virus vaccine, and Kenya inches towards the 5000 confirmed cases mark (current tally at 4738), things are getting real.
The total deaths have crossed 120 mark (123) while recovered is at 1607. As a Kenyan, I am worried about my family and loved ones as there seems to be no concrete treatment available. I have been reading up on the various treatments that are being tried/available in the other counties and it seems for a change Kenya is not alone in this conundrum.
Every day the tally of coronavirus patients keeps rising and it seems we keep breaking our own records of highest confirmed cases on a daily basis. The pandemic has taken an economic and emotional toll on people.
As I write this, I know of a lot of households that have seen someone lose their job and are struggling to maintain their normal lives, or even to put food on the table. While the world looks at each other for a possible vaccine, treatments are being discussed by the medical fraternity.
One of the many being discussed that I stumbled upon is Favipiravir which is being touted as a potential antiviral drug for the treatment of COVID-19. Many countries have already approved favipiravir for emergency use. It is the first and only drug that got approval for COVID-19 (approved for COVID-19 in Russia).
India’s drug regulator has approved the manufacturing and marketing of the oral antiviral drug Favipiravir for the treatment of mild to moderate COVID-19 patients as well as for restricted emergency use in the country.
The drug has demonstrated an encouraging response in mild to moderate COVID-19 patients during clinical trials. Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications. Because it is given in early intervention, it reduces strain on the healthcare system, with fewer people getting into a critical condition, and for a significant number of people, it is said to eliminate the virus within 10 days. As I read more about it, it seems that some media reports are calling it a ‘game-changer’ vis-a-vis early intervention treatment of Covid-19 in mild to moderate symptoms.
However, it comes with its own challenges. Pregnant women and people who have kidney or liver issues are advised to avoid it. Nevertheless, some of the medical professionals/organizations have called it a ‘most promising anti-COVID-19 drug in the world’ according to an article by DailyMail.
While countries like the UAE, Turkey, Egypt, India, Russia, China, and Japan have already started using it, I hope our authorities are taking note of this development. Obviously there are other drugs being discussed like hydroxychloroquine and remdesivir and I am hoping that our medical fraternity is looking at the world outside and taking cues from there as we really need to get back to our lives without fear of getting ill.
So while I read more about these treatments, I wish everyone safe and healthy days ahead.
About Soko Directory Team
Soko Directory is a Financial and Markets digital portal that tracks brands, listed firms on the NSE, SMEs and trend setters in the markets eco-system.Find us on Facebook: facebook.com/SokoDirectory and on Twitter: twitter.com/SokoDirectory
- January 2026 (220)
- February 2026 (248)
- March 2026 (287)
- April 2026 (207)
- May 2026 (192)
- June 2026 (238)
- July 2026 (279)
- August 2026 (214)
- January 2025 (119)
- February 2025 (191)
- March 2025 (212)
- April 2025 (193)
- May 2025 (161)
- June 2025 (157)
- July 2025 (227)
- August 2025 (211)
- September 2025 (267)
- October 2025 (297)
- November 2025 (230)
- December 2025 (220)
- January 2024 (238)
- February 2024 (227)
- March 2024 (190)
- April 2024 (133)
- May 2024 (157)
- June 2024 (145)
- July 2024 (136)
- August 2024 (154)
- September 2024 (212)
- October 2024 (255)
- November 2024 (196)
- December 2024 (143)
- January 2023 (182)
- February 2023 (203)
- March 2023 (322)
- April 2023 (297)
- May 2023 (267)
- June 2023 (214)
- July 2023 (212)
- August 2023 (257)
- September 2023 (237)
- October 2023 (264)
- November 2023 (286)
- December 2023 (177)
- January 2022 (293)
- February 2022 (329)
- March 2022 (358)
- April 2022 (292)
- May 2022 (271)
- June 2022 (232)
- July 2022 (278)
- August 2022 (253)
- September 2022 (246)
- October 2022 (196)
- November 2022 (232)
- December 2022 (167)
- January 2021 (182)
- February 2021 (227)
- March 2021 (325)
- April 2021 (259)
- May 2021 (285)
- June 2021 (272)
- July 2021 (277)
- August 2021 (232)
- September 2021 (271)
- October 2021 (303)
- November 2021 (364)
- December 2021 (249)
- January 2020 (272)
- February 2020 (310)
- March 2020 (390)
- April 2020 (321)
- May 2020 (335)
- June 2020 (327)
- July 2020 (333)
- August 2020 (276)
- September 2020 (214)
- October 2020 (233)
- November 2020 (242)
- December 2020 (187)
- January 2019 (251)
- February 2019 (215)
- March 2019 (283)
- April 2019 (254)
- May 2019 (269)
- June 2019 (249)
- July 2019 (335)
- August 2019 (292)
- September 2019 (306)
- October 2019 (313)
- November 2019 (362)
- December 2019 (318)
- January 2018 (291)
- February 2018 (213)
- March 2018 (275)
- April 2018 (223)
- May 2018 (235)
- June 2018 (176)
- July 2018 (256)
- August 2018 (247)
- September 2018 (255)
- October 2018 (282)
- November 2018 (282)
- December 2018 (184)
- January 2017 (183)
- February 2017 (194)
- March 2017 (207)
- April 2017 (104)
- May 2017 (169)
- June 2017 (205)
- July 2017 (189)
- August 2017 (195)
- September 2017 (186)
- October 2017 (235)
- November 2017 (253)
- December 2017 (266)
- January 2016 (164)
- February 2016 (165)
- March 2016 (189)
- April 2016 (143)
- May 2016 (245)
- June 2016 (182)
- July 2016 (271)
- August 2016 (247)
- September 2016 (233)
- October 2016 (191)
- November 2016 (243)
- December 2016 (153)
- January 2015 (1)
- February 2015 (4)
- March 2015 (164)
- April 2015 (107)
- May 2015 (116)
- June 2015 (119)
- July 2015 (145)
- August 2015 (157)
- September 2015 (186)
- October 2015 (169)
- November 2015 (173)
- December 2015 (205)
- March 2014 (2)
- March 2013 (10)
- June 2013 (1)
- March 2012 (7)
- April 2012 (15)
- May 2012 (1)
- July 2012 (1)
- August 2012 (4)
- October 2012 (2)
- November 2012 (2)
- December 2012 (1)
